Abivax SA Total Liabilities

Latest as of March 2026: €117.55 Million EUR ≈ $137.43 Million USD

Abivax SA total liabilities. Based on the latest financial reports, Abivax SA (ABVX) has total liabilities worth €117.55 Million EUR (≈ $137.43 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Abivax SA to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Abivax SA (2013–2025)

Total liabilities of Abivax SA from 2013 to 2025. This chart illustrates how Abivax SA's total liabilities have evolved over time, based on quarterly financial data. Explore ABVX strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Abivax SA Competitors by Total Liabilities

The table below lists competitors of Abivax SA ranked by their total liabilities.

Company	Country	Total Liabilities
SRF Limited NSE:SRF	India	Rs89.98 Billion
Shenzhen Kinwong Electronic Co Ltd SHG:603228	China	CN¥11.87 Billion
Sharetronic Data Technology Co Ltd SHE:300857	China	CN¥14.25 Billion
Shanghai Commercial & Savings Bank Ltd TW:5876	Taiwan	NT$2.23 Trillion
Spyre Therapeutics Inc. NASDAQ:SYRE	USA	$71.86 Million
BOK Financial Corporation NASDAQ:BOKF	USA	$47.79 Billion
Jackson Financial Inc NYSE:JXN	USA	$318.93 Billion
Jinduicheng Molybdenum Co Ltd SHG:601958	China	CN¥2.88 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down Abivax SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Abivax SA (ABVX) total assets.

Liquidity & Leverage Metrics

Abivax SA Total Liabilities Ratios Explained

Abivax SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	8.25	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.27	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.21	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Abivax SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Abivax SA (2013–2025)

The table below shows the annual total liabilities of Abivax SA from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	€129.14 Million ≈ $150.97 Million	-21.57%
2024-12-31	€164.64 Million ≈ $192.49 Million	+25.63%
2023-12-31	€131.05 Million ≈ $153.21 Million	+83.37%
2022-12-31	€71.47 Million ≈ $83.56 Million	-12.40%
2021-12-31	€81.59 Million ≈ $95.39 Million	+22.46%
2020-12-31	€66.62 Million ≈ $77.89 Million	+66.78%
2019-12-31	€39.95 Million ≈ $46.70 Million	+105.98%
2018-12-31	€19.39 Million ≈ $22.67 Million	+244.17%
2017-12-31	€5.63 Million ≈ $6.59 Million	+45.23%
2016-12-31	€3.88 Million ≈ $4.54 Million	-14.35%
2015-12-31	€4.53 Million ≈ $5.30 Million	+12.38%
2014-12-31	€4.03 Million ≈ $4.71 Million	-9.29%
2013-12-31	€4.44 Million ≈ $5.20 Million	--

About Abivax SA

PA:ABVX France Biotechnology

Market Cap

$7.87 Billion

€6.73 Billion EUR

Market Cap Rank

#2563 Global

#53 in France

Share Price

€77.15

Change (1 day)

-0.64%

52-Week Range

€63.10 - €135.00

All Time High

€135.00